Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Betamethasone diproprionate/calcipotriol - LEO Pharma

Drug Profile

Betamethasone diproprionate/calcipotriol - LEO Pharma

Alternative Names: Calcipotriene/betamethasone propionate; Calcipotriol/betamethasone diproprionate; Daivobet; Daivobet 50/500 Ointment; Daivobet Gel; Dovobet; Enstilar; LEO 90105; LEO-80185; LEO-90100; LEO90100 cutaneous spray; LP-0113; Taclonex; Taclonex Scalp; Xamiol

Latest Information Update: 18 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LEO Pharma
  • Developer Kyowa Hakko Kirin; LEO Pharma
  • Class Anti-inflammatories; Antipsoriatics; Cyclohexenes; Dihydroxycholecalciferols; Fluorinated steroids; Glucocorticoids; Indenes; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Plaque psoriasis; Psoriasis

Most Recent Events

  • 24 Jan 2019 LEO Pharma initiates enrolment in a phase III trial for Plaque psoriasis (Topical, Foam) in Japan (NCT03806790)
  • 23 Jan 2019 LEO Pharma plans a phase III trial for Plaque psoriasis (Topical) (NCT03806790)
  • 01 Jul 2018 LEO Pharma completes a phase I trial for healthy volunteers in Japan (Topical, Foam) (NCT03476746)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top